LONDON, Aug 8 (Reuters) - With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva (VLS.PA), opens new tab is betting big on a vaccine as it looks beyond disappointing ...
Valneva says it’s working with French regulators on next steps and pointed out that the country's health authority is maintaining its recommendation for Ixchiq’s use in people ages 18 to 64. (valneva) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results